Develop and commercialize seed technology and biotechnological events. Produce and market crop protection products, including herbicides and insecticides. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $333.3M a year. A small number, but proof the product has real buyers.
A loss of $55.4M against $333.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.42. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, BIOX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BIOX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.